Published July 26, 1990
by John Wiley & Sons Inc .
Written in English
|The Physical Object|
|Number of Pages||230|
Heparin for Prevention of Atherosclerosis. This article has no abstract; the first words appear below. To the Editor: As a middle-aged general surgeon who has recently undergone coronary. Kakkar V. V., Djazaeri B., Fok J., Fletcher M., Scully M. F. Heparin: pharmacological potentials from atherosclerosis to asthma and Westwick J. () Low-molecular weight heparin and prevention of post-operative deep vein by: Atherosclerosis -- or hardening of the arteries -- is the leading cause of heart attacks, strokes, and peripheral vascular disease. Find out more about atherosclerosis causes, symptoms, risk. 2. The therapeutic use of chronically inhaled heparin has been suggested as prophylaxis in atherosclerosis. 3. 3. Heparin, physiologically stored in mast cells of the respiratory system, has also been recently studied in the prevention of immunological and non-immunological asthmatic attacks. 4.
Prevention and treatment of arterial atherosclerosis using glycosaminoglycans Finally, we consider the importance of Engelberg, who during the past four decades has shown in his own patients what outstanding results can be obtained with heparin injections in the prevention and treat- ment of atherosclerotic disorders of the cardiac cir. An early documentation of the clinical trials of heparin was published in and the effectiveness of heparin treatment in the prevention of postoperative thrombosis was quickly established. The use of heparin also became essential for cardiovascular surgery to maintain extracorporeal circulation of blood through the heart-lung machine. Atherosclerosis as the main cause of thrombosis Occlusion of peripheral vessels is in more than 90% of cases caused by atherosclerosis leading to throm- Monitoring of treatment by heparin Antidotes of heparin Effect of heparin on vascular smooth muscle cell proliferation Indications of heparin Side-effects of heparin. Detailed Heparin dosage information for adults and children. Includes dosages for Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis, Deep Vein Thrombosis - Prophylaxis and more; plus renal, liver and dialysis adjustments.
The beneficial effects derived from flavonoids, with respect to cardiovascular disease prevention have been attributed to (i) their antioxidant activity , (ii) the prevention of atherosclerosis , and (iii) the effect on platelet aggregation . Many studies focused on the protective effects of flavanols such as catechin against. Introduction. Previous investigations have demonstrated that heparin has antithrombotic activity when administered orally in rat thrombosis models (1, 2).Several studies suggest that heparins are found on the endothelial surface within minutes following oral administration with minimal observed evidence of . Heparin cofactor II (HCII) is a serine protease inhibitor (serpin) that has been shown to be a predictor of decreased atherosclerosis in the elderly and protective against atherosclerosis in mice. HCII inhibits thrombin in vitro and HCII-thrombin complexes have been detected in human plasma. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet. Jun 6; 1 ()– [Sayen JJ, Singer RB, Peirce G, Horwitz O. Unstable angina, myocardial infarction, heparin and death: medium dose heparin (not exceed units/day) in the treatment of patients with acute coronary event--first year and.